Sobi said it plans to seek FDA approval of the gout drug, SEL-212, in 2024. If approved, it would compete against Krystexxa, a Horizon Therapeutics drug projected to become a blockbuster seller.
With support from Sanofi and the Juvenile Diabetes Research Foundation, Boston-based Selecta Biosciences has raised $20 million to advance drug candidates for Type 1 diabetes and severe gout. Of the gout program, CEO Werner Cautreels said in a statement: “SEL-212 is just the beginning for us, as we have identified many biopharmaceuticals, including existing and new classes of […]
3D medical animation services have emerged as a groundbreaking tool in the healthcare industry, revolutionizing the way medical concepts are taught, understood, and marketed.